news
COVID-19 is benefiting contract manufacturing services, suggest reports
Reports have found that the COVID-19 pandemic is providing new opportunities for contract and development manufacturing organisations (CDMOs).
List view / Grid view
Vaccine Technology
news
FDA grants Fast Track Designation to Novavax COVID-19 vaccine candidate
The FDA has given Fast Track Designation to NVX-CoV2373, Novavax’s COVID-19 vaccine candidate, created using recombinant nanoparticle technology.
![Artist's depiction of an ultrapotent COVID-19 vaccine candidate in which 60 pieces of a coronavirus protein (red) decorate nanoparticles (blue and white). The vaccine candidate was designed using methods developed at the UW Medicine Institute for Protein Design. The molecular structure of the vaccine roughly mimics that of a virus, which may account for its enhanced ability to provoke an immune response [Credit: Ian Haydon/ UW Medicine Institute for Protein Design].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Nanoparticle-covid-19-vaccine-300x278.jpg)
![Artist's depiction of an ultrapotent COVID-19 vaccine candidate in which 60 pieces of a coronavirus protein (red) decorate nanoparticles (blue and white). The vaccine candidate was designed using methods developed at the UW Medicine Institute for Protein Design. The molecular structure of the vaccine roughly mimics that of a virus, which may account for its enhanced ability to provoke an immune response [Credit: Ian Haydon/ UW Medicine Institute for Protein Design].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Nanoparticle-covid-19-vaccine.jpg)
news
Highly potent nanoparticle COVID-19 vaccine designed using computer
Developers suggest that the potency, stability and manufacturability of the nanoparticle vaccine candidate could enable vaccination against COVID-19 on a global scale.
news
Navigating the challenges of mass vaccine production
A new opinion piece from Watson-Marlow Fluid Technology Group has been launched.
news
Serum Institute of India: outsourced manufacturing of COVID-19 vaccines
As the COVID-19 pandemic and the search for an effective preventative vaccine continues, the Serum Institute of India has entered into manufacturing agreements with both Novavax and Codagenix to help supply their experimental COVID-19 vaccine candidates.
news
Oral COVID-19 vaccine candidate to enter Phase I human trials
Vaxart's application for a Phase I clinical trial to evaluate its oral COVID-19 vaccine candidate has been cleared by the FDA.
news
COVID-19 vaccine tablet induces systemic and mucosal immune responses
The researchers suggest inducing a mucosal immune response may be crucial to protect against SARS-CoV-2 infection and that the tablet formulation could overcome several major challenges associated with injectable vaccines.
article
Developing a preventive vaccine regimen to tackle Ebola
Earlier this year, Johnson & Johnson announced the first major regulatory approval of a vaccine developed by Janssen for the prevention of Ebola. Nikki Withers spoke with the Global Head of Vaccines, Johan Van Hoof, to discover what technologies were used and how they are now being leveraged to develop…
news
Collaboration to develop the world’s first prophylactic gonorrhoea vaccine
Therapyx and Intravacc will jointly develop NGoXIM, a microsphere vaccine which is designed to stimulate adaptive immunity against gonorrhoea.
article
COVID-19 vaccine: applying healthcare traceability learnings to ensure safe global distribution
Grant Courtney explains why traceability is vital for the current pandemic as it would guarantee that COVID-19 vaccines are safe, effective and suitably distributed.
news
Intranasal vaccine made from peptide nanofibres shows efficacy in mice
A new vaccine platform using self-assembling peptide nanofibres tagged with antigens has been tested successfully in mice, eliciting a strong immune response.
news
CureVac recieves €75 million loan for vaccine development and manufacturing expansion
The European Investment Bank (EIB) will provide three €25 million instalments to support CureVac’s vaccine development and expansion to mRNA production facilities.
news
Moderna and Catalent to collaborate on COVID-19 vaccine manufacture
Catalent's biologics facility will conduct large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate.
news
First patient dosed with COVID-19 vaccine using self-amplifying RNA
A Phase I clinical trial to test Imperial College London's COVID-19 vaccine candidate has been initiated, with the first patient dosed.
article
Bioprocessing & Bioproduction In-Depth Focus 2020
This in-depth focus includes articles detailing five important considerations for European companies entering the US biosimilar market and explaining why virally vectored DNA and mRNA vaccines could prevent the spread of COVID-19.
